Opus’ LYNX-2 Phase III Trial Hits Primary Endpoint for Post-LASIK Night Vision Treatment
Opus’ phentolamine eye drops hit the LYNX-2 letter-gain target on mesopic low contrast distance visual acuity. Opus Genetics (North Carolina,…
EssilorLuxottica to Acquire Optegra in Expanding Surgical Care
Group expands surgical footprint with 70+ Optegra clinics across EuropeEssilorLuxottica (Charenton-le-Pont, France) has entered into an agreement to acquire Optegra…
popular posts
latest posts
